| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| ln Vivo |
TRPC6-IN-3 (compound 17; 1–10 mg/kg; po; orally 12 h and 2 h before LPS challenge; LPS-induced mice) prevents vascular leakage caused by LPS and prevents the build-up of BALF protein (Broncho-Alveolar-Lavage protein) in a mouse model[1]. In mice induced with H1N1, TRPC6-IN-3 (3 mg/kg; po; daily, for 4 d) decreases vascular leakage caused by H1N1[1].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: LPS-induced mice[1]
Doses: 1, 3, and 10 mg/kg Route of Administration: Oral administration; orally 12 h and 2 h before LPS challenge Experimental Results: decreased BALF protein concentration of 56 % at 3 mg/kg and 62 % at 10 mg/kg. Animal/Disease Models: H1N1-induced mice[1] Doses: 3 mg/kg Route of Administration: Oral administration; daily, for 4 days Experimental Results: Inhibited Evans blue extravasation from the blood to the BALF and decreased BALF Evans blue by 24 % at 3 mg/kg. |
| References |
| Molecular Formula |
C22H22FN5O3
|
|---|---|
| Molecular Weight |
423.440187931061
|
| Exact Mass |
423.17
|
| CAS # |
2311863-36-0
|
| PubChem CID |
138674835
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.1
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
31
|
| Complexity |
584
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(N1CCC(C2=NN=C(N)C=C2)CC1)(C1=NC=C(OC2=CC=C(F)C=C2)C(OC)=C1)=O
|
| InChi Key |
JUALOUHZJJERQT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H22FN5O3/c1-30-19-12-18(25-13-20(19)31-16-4-2-15(23)3-5-16)22(29)28-10-8-14(9-11-28)17-6-7-21(24)27-26-17/h2-7,12-14H,8-11H2,1H3,(H2,24,27)
|
| Chemical Name |
[4-(6-aminopyridazin-3-yl)piperidin-1-yl]-[5-(4-fluorophenoxy)-4-methoxypyridin-2-yl]methanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL (295.20 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.91 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.91 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3616 mL | 11.8080 mL | 23.6161 mL | |
| 5 mM | 0.4723 mL | 2.3616 mL | 4.7232 mL | |
| 10 mM | 0.2362 mL | 1.1808 mL | 2.3616 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT07220083
Conditions:Focal Segmental GlomerulosclerosisLink: https://clinicaltrials.gov/ct2/show/NCT07355296
Conditions:Proteinuric Kidney DiseasesLink: https://clinicaltrials.gov/ct2/show/NCT07308652
Conditions:Healthy
Title:A Study in Healthy People to Test Whether BI 764198 Influences the Amount of Metformin in the Body
Status:Completed
updateDate:2026-04-14
Ctid:NCT07368569
Link: https://clinicaltrials.gov/ct2/show/NCT07368569
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT05213624
Conditions:Kidney Disease, ChronicLink: https://clinicaltrials.gov/ct2/show/NCT04604184
Conditions:COVID-19Link: https://clinicaltrials.gov/ct2/show/NCT03854552
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT04665700
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT04176536
Conditions:Healthy|Chronic Kidney DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT04102462
Conditions:HealthyProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
